Logotype for Option Care Health Inc

Option Care Health (OPCH) Q3 2024 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Option Care Health Inc

Q3 2024 earnings summary

17 Jan, 2026

Executive summary

  • Net revenue for Q3 2024 was $1.28 billion, up 17% year-over-year, driven by organic growth in both acute and chronic therapies, with strong performance in rare and orphan portfolios.

  • Net income for Q3 2024 was $53.9 million, down 4.3% compared to Q3 2023, with a net margin of 4.2%.

  • Gross profit margin declined to 20.1% from 23.3% year-over-year, mainly due to higher cost therapies and less favorable procurement dynamics.

  • Operational recovery from the Change Healthcare incident is largely complete, with no material financial impact in Q3 2024, though patient payment collections remain delayed.

  • Navigated significant supply chain disruptions from Hurricane Helene, impacting IV solution availability and limiting new acute patient onboarding, with effects expected to continue into Q4.

Financial highlights

  • Revenue grew 17% year-over-year, with rare and orphan portfolios and established therapeutic categories as key drivers.

  • Gross profit dollars increased by $7.3 million sequentially from Q2; Q3 gross profit was $256.7 million.

  • Adjusted EBITDA reached $115.6 million, representing 9% of revenue and 5.3% growth over the prior year.

  • Cash flow from operations was $160.4 million for the quarter; cash balance stood at $483 million after $41.9 million in share repurchases.

  • For the nine months ended September 30, 2024, net income was $151.7 million on $3.65 billion revenue.

Outlook and guidance

  • Full-year 2024 revenue expected at $4.9–$4.95 billion; adjusted EBITDA guidance at $438–$443 million.

  • At least $300 million in cash flow from operations anticipated for 2024; effective tax rate projected at 26%-28%.

  • No 2024 impact from Stelara pricing changes; material gross profit impact expected in 2025, with further guidance to be provided in Q4 call.

  • Guidance reflects anticipated negative impact from ongoing supply chain disruption.

  • Medium- and long-term growth outlook remains high single-digit top-line and low double-digit enterprise growth.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more